Momota Hiroyuki, Holland Eric C
Department of Cancer Biology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Curr Opin Biotechnol. 2005 Dec;16(6):681-6. doi: 10.1016/j.copbio.2005.10.012. Epub 2005 Nov 2.
As continuous cell proliferation caused by genetic alterations leads to cancer, monitoring abnormal cell proliferation in sporadic tumor models is important in the context of tumor generation, development and response to therapy. Bioluminescence imaging technology, which visualizes the conversion of chemical energy into visible light by luciferase enzymes, is an established method to measure cell numbers in grafted tumors in vivo, but has not been used to monitor cell proliferation per se. To measure cell proliferation noninvasively, transgenic mice have been developed that express the luciferase gene under the control of the E2F1 promoter. When these reporter mice are crossed with genetically defined mouse models of human cancer, the proliferative activity of the tumor cells can be monitored with proportional light production. These technologies support more detailed preclinical trials and could enable other biological pathways to be monitored in living cells.
由于基因改变导致的细胞持续增殖会引发癌症,因此在散发性肿瘤模型中监测异常细胞增殖对于肿瘤的发生、发展以及对治疗的反应而言至关重要。生物发光成像技术可将化学能通过荧光素酶转化为可见光,是一种用于测量体内移植肿瘤中细胞数量的成熟方法,但尚未用于监测细胞增殖本身。为了无创地测量细胞增殖,已开发出在E2F1启动子控制下表达荧光素酶基因的转基因小鼠。当这些报告基因小鼠与人类癌症的基因定义小鼠模型杂交时,肿瘤细胞的增殖活性可通过成比例的发光进行监测。这些技术支持更详细的临床前试验,并能够监测活细胞中的其他生物学途径。